kairospharma.com - רווח תפעולי EBITDA KAPA

The development of therapeutic platforms at Kairos Pharma Ltd (KAPA) is leading to rising costs in the absence of operating leverage. The company's EBITDA demonstrates profit volatility, where 0.00 captures the current value of the indicator. Stability is provided by California centers and CDMO outsourcing, while success depends on FDA approval and the funding of clinical trials to combat cancer resistance.

Investors in Kairos Pharma Ltd (KAPA) must account for binary outcome risks due to the company's narrow specialization in combating cancer therapy resistance. This metric measures cash flow from core operations before depreciation, reflecting the business's actual ability to act as a cash generator, which, on the EBITDA chart, allows for the identification of abnormal liquidity spikes and prevents overpaying for the asset.